WO2005023282A1 - 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 - Google Patents
生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 Download PDFInfo
- Publication number
- WO2005023282A1 WO2005023282A1 PCT/JP2004/012718 JP2004012718W WO2005023282A1 WO 2005023282 A1 WO2005023282 A1 WO 2005023282A1 JP 2004012718 W JP2004012718 W JP 2004012718W WO 2005023282 A1 WO2005023282 A1 WO 2005023282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticles
- peptide
- nanoparticle
- divalent
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Nanoparticle containing bioactive protein or peptide, method for producing the same, and external preparation comprising the nanoparticle
- the present invention relates to a nanoparticle containing a bioactive protein or peptide, and more particularly, to a nanoparticle containing a bioactive protein or peptide, a method for producing the nanoparticle, and an external preparation comprising the nanoparticle.
- bioactive proteins are inactivated by peptidases present in the digestive tract, which are macromolecules and poorly absorbed, they cannot be administered orally, and are usually administered to the body by injection. However, such a method may cause pain at the injection site for the patient, which is not desirable. Also, administration at regular intervals can cause significant inconvenience to the patient. Therefore, development of a non-injectable administration method that is simple and easy to administer safely and frequently is desired.
- Patent Document 1 a preparation in which a physiologically active protein is encapsulated in poorly water-soluble calcium-containing inorganic particles (Patent Document 1), a water-insoluble sustained-release composition comprising a precipitate of a physiologically active protein or peptide and zinc ions (Patent Document 2) And so on.
- Patent Document 2 a water-insoluble sustained-release composition comprising a precipitate of a physiologically active protein or peptide and zinc ions
- Patent Document 1 International Publication WO 02/096396
- Patent Document 2 JP 2003-081865 A
- Non-Patent Document 1 DRUG DELIVERY SYSTEM Today's DDS Drug Delivery System (Pharmaceutical Journal) 325-331, 1999
- Non-patent document 2 Clinical pharmacology (Jpn. J. Clin. Pharmacol. Ther.,) 26 (1), p.127-128 (1995)
- Non-patent document 3 Yakugaku Zasshi, 121 (12), p.929- 948 (2001)
- Non-Patent Document 4 J. Controlled Release, 79, p.81-91 (2002)
- a physiologically active protein cannot exert its medicinal effect by oral administration, and is mainly obtained by injection administration. Therefore, in order to relieve the pain caused by injection to patients and to simplify the administration method capable of self-administration, an administration method via the skin or mucous membrane is effective as a non-oral administration method instead of injection administration.
- an administration method via the skin or mucous membrane is effective as a non-oral administration method instead of injection administration.
- the emergence of a drug having high bioabsorbability and bioavailability that is still unsatisfactory in terms of absorbability and bioavailability is strongly desired in the medical field. Disclosure
- the present invention relates to a method for administration via the skin and mucous membranes of physiologically active proteins or peptides which have not been able to exert their medicinal properties by oral administration and have been mainly administered by injection. Accordingly, it is an object of the present invention to provide a technique which is excellent in absorbability in a living body, can exhibit high resilience and can exhibit bioavailability.
- the inventors of the present invention have intensively studied to solve such problems, and as a result, have applied nanotechnology. Using special nanoparticles, which are much smaller than red blood cells, and succeeded in incorporating bioactive proteins or peptides into them. When administered, the bioactive protein or peptide contained in the nanoparticles was highly absorbed into the living body, and it was found that the bioavailability was excellent, leading to the completion of the present invention. .
- the present invention provides a nanoparticle containing a bioactive protein or peptide, which has excellent absorbability and nouria virility when administered to the skin or mucosa.More specifically, the present invention provides
- a biologically active protein or peptide a water-insoluble substance, preparing primary nanoparticles using the water-insoluble substance, a medium- to long-chain organic compound having a hydrophobic group and an anionic residue, and a surfactant, and preparing the primary nanoparticle.
- a nanoparticle containing a bioactive protein or peptide obtained by sequentially contacting the nanoparticle with a divalent or trivalent metal salt, and a divalent or trivalent basic salt,
- the secondary nanoparticles dissolve or suspend a water-insoluble substance, a medium- to long-chain organic compound having both hydrophobic groups and anionic residues, and a surfactant in an organic solvent or a water-containing organic solvent.
- Nanoparticles according to (1) which are made by adding them while dispersing in water
- Bioactive protein or peptide power insulin interferon, interferon_ / 3, interferon- ⁇ , growth hormone, G_CSF, GM_CSF, erythropoietin, thrombopoetin, perokinase, t_PA, IL_11, ethanenorecept, infliximab, S ⁇ D, FGF, EGF, HGF, NGF, BDNF, leptin, NT-3, antigen, antibody, enzyme, calcitonin, PTH, ACTH, GnRH, TRH and vasopressin (1) Nanoparticles according to 4),
- Means for converting a physiologically active protein or peptide into a water-insoluble substance is a bivalent or trivalent means.
- the nanoparticles according to (1) which are any of means for contacting with a metal ion, contacting with an acidic or basic polysaccharide, adjusting pH, or changing ionic strength,
- Bivalent or trivalent metal ion force for bringing a biologically active protein or peptide into contact with water to make it insoluble in water. It is selected from zinc ion, calcium ion, iron ion and copper ion. Described nanoparticles,
- the medium- to long-chain organic compound having both a hydrophobic group and an anionic residue is selected from myristic acid, oleic acid, lauric acid, palmitic acid and salts thereof (1) to (4). Described nanoparticles,
- the divalent or trivalent metal salt to be brought into contact with the primary nanoparticles is a calcium salt, a zinc salt, an iron salt or a copper salt, and the divalent or trivalent basic salt is a carbonate, a phosphate or a salt.
- the external preparation is selected from ointments, gels, nasal drops, eye drops, sprays, inhalants, suspensions, patches, patches and tablets for oral mucosa (10 )
- a physiologically active protein or peptide is made water-insoluble, and the water-insoluble, medium- to long-chain organic compound having a hydrophobic group and an anionic residue and a surfactant are dissolved or suspended in an organic solvent or a water-containing organic solvent.
- the solution becomes turbid, and this solution is added to a large amount of water while dispersed to produce primary nanoparticles.
- the solution containing the primary nanoparticles contains a divalent or trivalent metal salt and a divalent or trivalent basic salt.
- the means for converting a physiologically active protein or peptide into a water-insoluble substance is contact with a divalent or trivalent metal ion, and the divalent or trivalent metal salt to be brought into contact with the primary nanoparticles is potassium salt.
- the nanoparticle provided by the present invention is intended to absorb a bioactive protein or peptide contained therein via the skin or mucous membrane, and exhibits bioabsorbability that can be substituted for injection administration. It is. Therefore, a bioabsorbable bioactive protein and peptide having a high absorbency, which has not been achieved until now, has an epoch-making effect that enables transdermal or transmucosal absorption of a bioactive protein or peptide that has been achieved. It has an excellent effect that an external preparation containing it is created.
- FIG. 1 is a graph showing changes in blood glucose levels of mice in Test Example 1.
- ⁇ indicates 0 ⁇ g / control for control, 10 ⁇ g / mouse for transdermal administration, and 10 ⁇ g for nanoparticle administered transmucosally.
- X means 1 ⁇ g Z animals usually administered insulin, and the average blood glucose level is 430 mg / 100 mL.
- the present invention uses a physiologically active protein or peptide as a water-insoluble substance, and uses the water-insoluble substance, a medium- to long-chain organic compound having both a hydrophobic group and an anionic residue, and a surfactant.
- a physiologically active protein or peptide uses the water-insoluble substance, a medium- to long-chain organic compound having both a hydrophobic group and an anionic residue, and a surfactant.
- To form primary nanoparticles and then contain the bioactive protein or peptide obtained by sequentially contacting the primary nanoparticles with a divalent or trivalent metal salt and a divalent or trivalent basic salt.
- Nanoparticles, a method for producing the nanoparticles, and an external preparation comprising the nanoparticles.
- the nanoparticles of the present invention have a diameter of about 1150 nm, preferably about 10-80 nm.
- a particle diameter can be adjusted by the mixing ratio of the water-insoluble substance of the physiologically active protein or peptide to the medium- and long-chain organic compound to be contained, the amount of the solvent to be used, and the stirring intensity. Can be produced. It was found that increasing the amount of the medium- and long-chain organic compounds reduced the particle size.
- the particle diameter can be measured by a light scattering method or an electron microscope.
- the physiologically active protein or peptide contained in the nanoparticles provided by the present invention is not particularly limited, but those which form a precipitate with a divalent or trivalent metal salt are preferred.
- bioactive proteins or peptides include insulin, interface Elongone, interferon-i3, interferon-gamma, growth hormone, G-CSF, GM_CSF, erythropoietin, thrombopoetin, perokinase, t-PA, IL-11, etanonerecept, infliximab, S ⁇ D, FGF, EGF, HGF , NGF, BDNF, leptin, NT_3, antigen, antibody, various enzymes, calcitonin, PTH, ACTH, GnRH, TRH or vasopressin.
- insulin, interferon-one, interferon- /, interferon- ⁇ , human growth hormone and erythropoietin are particularly preferred.
- a physiologically active protein or peptide is first made into a water-insoluble substance.
- the most preferable means for making this a water-insoluble substance is to use a divalent or trivalent metal ion which forms a precipitate with a bioactive protein or peptide.
- divalent or trivalent metal ions include zinc ions derived from zinc salts such as zinc chloride, zinc sulfate, and zinc acetate; calcium ions derived from calcium salts such as calcium chloride, calcium sulfate, and calcium carbonate; And iron ions such as iron salts such as iron sulfide; copper ions such as copper salts such as copper chloride and copper sulfate.
- zinc ions can be preferably used.
- the combination ratio of the physiologically active protein or peptide and the divalent or trivalent metal ion is not particularly limited, and may be a ratio sufficient to form a water-insoluble substance by binding of both substances.
- the weight ratio of the physiologically active protein or peptide to the zinc salt is preferably about 10: 1 to 1: 2.
- Other water insolubilization methods include contacting with acidic or basic polysaccharides such as sodium chondroitin sulfate, hyanoreonic acid, and chitosan, or adjusting ⁇ of a solution in which a physiologically active protein or peptide is dissolved, or changing the ionic strength. It is also possible. If the physiologically active protein or peptide itself is water-insoluble, it can be used as it is.
- a compound having both a hydrophobic group and an anionic residue such as a carboxyl group, a phosphate group, and a sulfate group.
- Any organic compound having both a hydrophobic group and an anionic residue can be used, and among them, a medium- to long-chain organic compound having a carboxyl group is particularly preferable. That As such medium- and long-chain organic compounds, myristic acid, oleic acid, lauric acid, and palmitic acid are preferred.
- the medium- to long-chain organic compound can be added as it is when it is a powder, but it is preferable to use it after dissolving it in an organic solvent or a water-containing organic solvent.
- acetone As such an organic solvent, acetone; lower alcohols such as methanol, ethanol, propanol and butanol can be used, and among them, acetone and ethanol are preferable.
- the blending weight ratio of the physiologically active protein or peptide to the medium- and long-chain organic compound is preferably about 1: 0.5-11: 0.03.
- a surfactant in order to avoid aggregation of the generated nanoparticles. And a molar ratio of about 0.3 to 0.03 with respect to the medium- to long-chain organic compound.
- a surfactant include polio-hardened castor oil, polyethylene glycol fatty acid ester, polio-fatty acid ester (Tween series), polyoxyethylene fatty acid ester, polyoxyethylene alkyl ether, sorbitan fatty acid ester, glycerin fatty acid ester, and polyoxy fatty acid ester.
- a nonionic surfactant such as ethylene polyoxypropylene glycol can be used, and among them, polyoxyethylene sorbitan fatty acid ester (Tween series) is preferable.
- the most important feature of the present invention is that a biologically active protein or peptide is made into a water-insoluble substance, and the water-insoluble substance, a medium- to long-chain organic compound, and a surfactant are used to prepare primary nanoparticles.
- the primary nanoparticles are sequentially contacted with a divalent or trivalent metal salt and a divalent or trivalent basic salt, the metal salt and the basic salt are sequentially bonded, and as a result, the primary nanoparticles Is a conjugate having a state in which a water-insoluble metal salt covers the periphery of the conjugate.
- the force, and thus the conjugate itself, is the nanoparticle itself, which is surprisingly, when the nanoparticle is transdermally or transmucosally administered, It acts as a carrier and satisfactorily absorbs the biologically active protein or peptide contained therein, and its bioabsorbability is high and can replace injection.
- Examples of the divalent or trivalent metal salt used include calcium chloride, calcium acetate, and sulfuric acid.
- Calcium salts such as calcium acid; zinc salts such as zinc acetate, zinc chloride and zinc sulfate; iron salts such as iron chloride and iron sulfide; or copper salts such as copper chloride and copper sulfide, and calcium salts among others.
- Shiridani calcium is preferred.
- the blending amount of the metal salt cannot be generally limited, but is preferably about 30.01 by weight based on the physiologically active protein or peptide as the active ingredient.
- Examples of the divalent or trivalent basic salt include carbonates such as sodium carbonate, potassium carbonate, and calcium carbonate; phosphates such as sodium phosphate, potassium phosphate, and calcium phosphate; sodium oxalate; Oxalates such as potassium oxalate and calcium oxalate; lactates such as sodium lactate, potassium lactate and calcium lactate; urates such as sodium urate, potassium urate and calcium urate; among others, carbonates, especially sodium carbonate Is preferred.
- the amount of the basic salt may be unconditionally limited, but is preferably about 1.0 to 0.05 in a molar ratio to the above-mentioned metal salt.
- a bioactive protein or peptide is dissolved in acidic, basic or neutral water, and a divalent or trivalent metal ion is added to the solution to convert the bioactive protein or peptide into a water-insoluble substance.
- a solution in which a medium- to long-chain organic compound and a surfactant are dissolved in an organic solvent or a water-containing organic solvent is added, dissolved or suspended, and this solution is added while being dispersed in a large amount of water. By stirring this solution for about 110 minutes, primary nanoparticles are produced.
- the solution of the nanoparticles containing the bioactive protein or peptide of the present invention thus produced is freeze-dried, dried under reduced pressure, spray-dried and the like to remove the solvent, and as a composition for pharmaceutical preparation, By using the formulation base, additives, etc. as appropriate, it is possible to prepare a desired external preparation.
- the present invention also provides an external preparation for skin and mucous membranes containing as an active ingredient nanoparticles containing such a physiologically active protein or peptide.
- external preparations include systemic and topical administration.
- Spray, etc. specifically, ointments, gels, nasal drops, eye drops, sprays, inhalants, suspensions, cataplasms, patches, oral mucosa Tablets and the like can be given.
- the effective dosage form is application to the skin or mucous membranes, spraying into the upper respiratory tract, and the like.
- Examples of the base and other additive components used in the preparation of these external preparations include the bases and components pharmaceutically used in the preparation of the external preparation.
- Specific examples include petroleum bases such as petrolatum, plastibase, paraffin, liquid paraffin, light liquid paraffin, salami roe, silicone oil, etc.1J; water, macrogol, ethanol, methyl ethyl ketone, cottonseed oil, olive oil, peanut oil, etc.
- Nonionic surfactants such as polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene alkyl ether, sorbitan fatty acid ester, and polyoxyethylene polyoxypropylene glycol
- Stabilizers such as ruene
- humectants such as glycerin, 1,3-butylene glycol, propylene glycol, urea, sucrose, erythritol, and sorbitol
- Preservatives and the like can be appropriately selected and used according to the dosage form.
- ointment containing the nanoparticles of the present invention as an active ingredient petroleum jelly is used as a base and the like, and the suspension is stabilized as a gel for mouth mouth.
- CMC sodium carboxymethylcellulose
- Insulin lmg (21 IU) was dissolved in 0.011 ⁇ hydrochloric acid. To this solution was added 0.4 mg of chlorine chloride, and in the next batch, 6.5 mg of myristic acid was dissolved in 100 zL of acetone. 10 ⁇ L of the solution to which 30 ⁇ L was added was added. To this solution, 2 ⁇ L of Tween80 was added, and 98 / L of distilled water was added and stirred. The above mixture was added to 5 mL of distilled water and stirred well to produce primary nanoparticles.
- a predetermined amount of insulin was redispersed in vaseline or a 1% CMC aqueous solution and mixed to obtain an ointment or sol.
- the ointment or sol produced as described above (hereinafter sometimes referred to as “the present preparation”) was used in the following animal experiments.
- a nanoparticle of the present invention was produced by performing the same operation as in Example 1 except that a 5 M aqueous zinc acetate solution 15 / i L was used instead of the 5 M calcium chloride aqueous solution 15 / i L in Example 1.
- Test Example 1 Skin / mucosal permeability test
- Example 1 Using a male / female, 10-week-old (weight 40-46 g), 3-4 animals per group, shaving the back of the mouse with an electric clipper so as not to damage the skin surface, and using the method of Example 1.
- the preparation (insulin amount: 10 ⁇ g) obtained in the above was applied to the back and absorbed percutaneously.
- mice To examine transmucosal absorption, another group of mice was used, and the same nasal preparation (amount of insulin: 10 g) was sprayed on the nasal mucosa to absorb the mucosa.
- mice Yet another group of mice was injected subcutaneously with normal insulin (1 ⁇ g insulin). In addition, another group of 3 animals was not administered and served as a control.
- tail vein force and blood were collected before the test administration and every 1, 2, 4, 5, 6 and 7 hours after the administration, and the blood glucose level was measured using a Darco Card Diameter (Arkray Factory Inc.). ) was measured.
- tail vein blood was collected before administration and every 15, 40, 60, and 80 minutes after administration, and the blood glucose level was measured using the Gnoreco Card Diame The measurement was performed using data.
- the blood glucose level before administration of each mouse was defined as 100%, and the decrease (%) in the blood glucose level is shown in FIG.
- the data for subcutaneous insulin administration are data up to 80 minutes after administration.
- this formulation which contains insulin-containing nanoparticles as an active ingredient, has remarkable merit for patients and is extremely clinically effective as compared to the conventional insulin administration formulation by injection administration.
- nanoparticles of the present invention containing human growth hormone.
- the particle size of the nanoparticles contained in this solution was measured by a light scattering method. Most of the The diameter of the nanoparticles was 10-90 nm. In particular, when 0.3 mg of myristic acid was added, the particle with a particle size of 50 nm was most often present.
- An external patch (aqueous cataplasm) was obtained by a conventional method based on the above-mentioned components.
- the present invention uses a physiologically active protein or peptide as a water-insoluble substance, and uses the water-insoluble substance, a medium- to long-chain organic compound having both a hydrophobic group and an anionic residue, and a surfactant. Containing primary and secondary bioactive proteins or peptides obtained by sequentially contacting the primary nanoparticles with a divalent or trivalent metal salt and a divalent or trivalent basic salt. Nanoparticles.
- the nanoparticles of the present invention allow the bioactive protein or peptide contained therein to be absorbed into the body via skin or mucous membranes, and exhibit a bioabsorbability that can be substituted for injection administration.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-312031 | 2003-09-03 | ||
JP2003312031A JP2006199589A (ja) | 2003-09-03 | 2003-09-03 | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005023282A1 true WO2005023282A1 (ja) | 2005-03-17 |
Family
ID=34269728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012718 WO2005023282A1 (ja) | 2003-09-03 | 2004-09-02 | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2006199589A (ja) |
WO (1) | WO2005023282A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098205A1 (en) * | 2005-09-15 | 2009-04-16 | Council Of Scientife & Industrial Research | pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES |
EP2054339A2 (en) * | 2006-08-11 | 2009-05-06 | Panacea Biotec Ltd | Particles for delivery of active ingredients, process of making and compositions thereof |
US8841342B2 (en) | 2002-08-09 | 2014-09-23 | Vital Health Sciences Pty. Ltd. | Carrier |
US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US9314527B2 (en) | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
US9486409B2 (en) | 2006-12-01 | 2016-11-08 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
US9724299B2 (en) | 2006-12-01 | 2017-08-08 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
US10532019B2 (en) | 2005-12-01 | 2020-01-14 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9079874B2 (en) | 2007-12-14 | 2015-07-14 | Ezaki Glico Co., Ltd. | α-Lipoic acid nanoparticles and methods for preparing thereof |
JP5531230B2 (ja) * | 2009-07-16 | 2014-06-25 | 公益財団法人宮崎県産業振興機構 | 油性外用製剤及びその製造方法 |
EP2842545B1 (en) * | 2012-04-24 | 2020-02-12 | Osaka University | Method for producing an aqueous dispersion of drug nanoparticles and use thereof |
EP3235493A4 (en) * | 2014-12-19 | 2018-05-30 | Sekisui Chemical Co., Ltd. | Preparation |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
JPS557228A (en) * | 1978-06-29 | 1980-01-19 | Lion Corp | Enzyme preparation |
JPS6191130A (ja) * | 1984-10-04 | 1986-05-09 | モンサント コンパニー | 生物学的活性ポリペプチドの遊離延長組成物 |
JPH03275633A (ja) * | 1990-03-23 | 1991-12-06 | Teikoku Seiyaku Co Ltd | 生理活性ポリペプチドの吸収促進剤 |
JP2001518916A (ja) * | 1997-03-20 | 2001-10-16 | ノボ ノルディスク アクティーゼルスカブ | 結晶インスリンを含有する肺投与のための治療用粉末調合物 |
JP2001518915A (ja) * | 1997-03-20 | 2001-10-16 | ノボ ノルディスク アクティーゼルスカブ | インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法 |
JP2001526634A (ja) * | 1997-01-16 | 2001-12-18 | マサチューセッツ インスティチュート オブ テクノロジー | 吸入用粒子の調製 |
WO2002011695A2 (en) * | 2000-08-07 | 2002-02-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
JP2003519651A (ja) * | 2000-01-14 | 2003-06-24 | ブラウン ユニバーシティ リサーチ ファウンデーション | 微紛化凍結乾燥粒子 |
-
2003
- 2003-09-03 JP JP2003312031A patent/JP2006199589A/ja active Pending
-
2004
- 2004-09-02 WO PCT/JP2004/012718 patent/WO2005023282A1/ja unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
JPS557228A (en) * | 1978-06-29 | 1980-01-19 | Lion Corp | Enzyme preparation |
JPS6191130A (ja) * | 1984-10-04 | 1986-05-09 | モンサント コンパニー | 生物学的活性ポリペプチドの遊離延長組成物 |
JPH03275633A (ja) * | 1990-03-23 | 1991-12-06 | Teikoku Seiyaku Co Ltd | 生理活性ポリペプチドの吸収促進剤 |
JP2001526634A (ja) * | 1997-01-16 | 2001-12-18 | マサチューセッツ インスティチュート オブ テクノロジー | 吸入用粒子の調製 |
JP2001518916A (ja) * | 1997-03-20 | 2001-10-16 | ノボ ノルディスク アクティーゼルスカブ | 結晶インスリンを含有する肺投与のための治療用粉末調合物 |
JP2001518915A (ja) * | 1997-03-20 | 2001-10-16 | ノボ ノルディスク アクティーゼルスカブ | インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法 |
JP2003519651A (ja) * | 2000-01-14 | 2003-06-24 | ブラウン ユニバーシティ リサーチ ファウンデーション | 微紛化凍結乾燥粒子 |
WO2002011695A2 (en) * | 2000-08-07 | 2002-02-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
Non-Patent Citations (1)
Title |
---|
MAA Y. ET AL.: "Spray drying of air liquid interface sensitive recombinant human growth hormone", J. PHARM. SCI., vol. 87, no. 2, 1998, pages 152 - 159, XP000729419 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841342B2 (en) | 2002-08-09 | 2014-09-23 | Vital Health Sciences Pty. Ltd. | Carrier |
US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US20090098205A1 (en) * | 2005-09-15 | 2009-04-16 | Council Of Scientife & Industrial Research | pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES |
US10576034B2 (en) | 2005-12-01 | 2020-03-03 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US10532019B2 (en) | 2005-12-01 | 2020-01-14 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
EP2054339A2 (en) * | 2006-08-11 | 2009-05-06 | Panacea Biotec Ltd | Particles for delivery of active ingredients, process of making and compositions thereof |
EP2054339A4 (en) * | 2006-08-11 | 2011-08-03 | Panacea Biotec Ltd | PARTICULARS FOR ACTIVE INHIBITION, MANUFACTURING METHOD AND COMPOSITIONS THEREOF |
US9486409B2 (en) | 2006-12-01 | 2016-11-08 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
US9724299B2 (en) | 2006-12-01 | 2017-08-08 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10758485B2 (en) | 2006-12-01 | 2020-09-01 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10905637B2 (en) | 2006-12-01 | 2021-02-02 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
US10285941B2 (en) | 2006-12-01 | 2019-05-14 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
US9314527B2 (en) | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
Also Published As
Publication number | Publication date |
---|---|
JP2006199589A (ja) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005023282A1 (ja) | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
JP3249147B2 (ja) | 生理活性蛋白含有経口製剤 | |
US5574006A (en) | Nasally administrable peptide compositions on hydroxyapatite carriers | |
CA2332559C (en) | High molecular weight medicine-containing preparation in powder form for administration through mucosa | |
EP0566135A1 (en) | Transmucosal composition comprising a peptide and a cytidine derivative | |
JP4627727B2 (ja) | 多価金属無機塩被覆レチノイン酸ナノ粒子含有組成物 | |
WO1999033490A1 (fr) | Compositions medicinales a liberation prolongee | |
WO1994008599A9 (en) | Ion-pairing of drugs for improved efficacy and delivery | |
JP3283288B2 (ja) | 生理活性ペプチド製剤 | |
JP2002533378A (ja) | タンパク質の徐放用ポリオール/油懸濁液 | |
KR20010012374A (ko) | 지속 효과를 갖는 서방성 겔 | |
EP1561460B1 (en) | Nanoparticles for the administration of active ingredients, method of producing said particles and composition containing same | |
JP2003523399A (ja) | 上皮細胞成長因子を有効成分とする安定した組成物 | |
JPH08268905A (ja) | コロイド状絹フィブロイン及びそれを含有する組成物 | |
JP3770666B2 (ja) | 経粘膜吸収製剤用組成物 | |
WO2001032218A1 (en) | Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing | |
US20080260843A1 (en) | transpulmonary composition | |
JP3047948B2 (ja) | ペプチド類経鼻投与用組成物 | |
JP3624158B2 (ja) | ヒト上皮成長因子を含有する皮膚外用剤組成物 | |
CA2518102C (en) | Powdery preparation for nasal administration | |
JP3572092B2 (ja) | 線維芽細胞成長因子含有フィルム製剤 | |
CN1343129A (zh) | 持续释放的药学活性肽盐及其生产 | |
TWI291874B (ja) | ||
JPH11116485A (ja) | スクラルファート懸濁液製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP |